Waxman Asks FDA Not To Issue Guidance On Off-Label Promotion
This article was originally published in The Gray Sheet
Executive Summary
Rep. Henry Waxman, chair of the House Committee on Oversight and Government Reform, is urging FDA not to go forward with a guidance that he says would allow companies to use journal articles to promote off-label uses of devices and drugs